Aerobiotix, Inc. Announces Strategic Partnership with APIC

Jan 20, 2021 | News, News and Events

MIAMISBURG, Ohio–(BUSINESS WIRE)–Aerobiotix today announced a strategic partnership with the Association for Professionals in Infection Control and Epidemiology (APIC), the largest association for infection prevention and control (IPC) professionals. Since 2018, Aerobiotix has been a Strategic Partner and has again signed on as a 2021 APIC Strategic Partner.

“Aerobiotix is pleased to partner with APIC to help prevent the spread of infection and expand education and resources for IPs”

Tweet this

According to the Centers for Disease Control and Prevention, an estimated 633,000 hospitalized patients get healthcare associated infections (HAIs) each year and 72,000 die during their hospital stay. With the onset of the COVID-19 pandemic in 2020, the importance of providing state-of-the-art education and support services for professionals in infection prevention and control was further reinforced.

The APIC Strategic Partner program establishes long-term relationships with industry partners united in the common goal of reducing the risk of infection. APIC Strategic Partners play an important role in supporting many of the educational initiatives and services that benefit APIC’s almost 16,000 infection preventionist (IP) members fighting on the front-lines against the spread of harmful microorganisms and viruses, such as C. diff, MRSA, and SARS-CoV-2 in healthcare facilities.

“Aerobiotix is pleased to partner with APIC to help prevent the spread of infection and expand education and resources for IPs,” said Dr. Kirschman, CEO. “We share APIC’s patient safety mission and hope this partnership will help to strengthen APIC’s efforts to create a safer world through the prevention of infection.” Dr. Kirschman further states, “We look forward to bringing our educational opportunities to APIC’s members in airborne transmissions and their effect on infection rates.”

APIC Strategic Partners fully support the Competency Advancement Assistance (CAA) Program to help IPs further their education by managing the cost associated with obtaining the Certification in Infection Prevention and Control (CIC®) credential. The CAA program covers exam fees and study resources for up to 50 IPs annually.

“We are excited to welcome Aerobiotix as an APIC Strategic Partner,” said APIC CEO Devon Jopp. “Together, APIC and Aerobiotix will work together to improve healthcare outcomes and advance education and certification for IPC professionals.”

About Aerobiotix:

AEROBIOTIX® is a medical device company improving patient outcomes by transforming the physical environment of care. We utilize proprietary technologies to remove airborne microorganisms within acute environments and deliver measurable, data-driven, and peer-supported improvements to patient outcomes and staff safety. Visit us at www.aerobiotix.com.

First launched in 2017, the ILLUVIA® Air Disinfection System is a mobile air handling device which uses novel photolysis and mechanical filtration technologies to achieve air disinfection. It is intended to produce a directed, nonturbulent flow of air that has been treated to remove microorganisms to provide an area free of contaminants in critical healthcare settings, including surgical and procedural areas.

 

Contacts

Ann Dunham
Marketing Manager
Aerobiotix, Inc.
adunham@aerobiotix.com
888-978-7087, ext. 103

 

DAVID KIRSCHMAN, M.D.

President and CEO

The founder and CEO is David Kirschman, M.D., a former physician with extensive experience as CEO, Director, Chief Scientific Officer and operator in the orthopedic and biologic medical device space. Dr. Kirschman holds 55 issued US Patents for a wide range of medical devices. He received his BS in Biological Science cum laude from Colorado State University and M.D. from University of Colorado School of Medicine.

GREGORY CARROLL PH.D.

Director Scientific Affairs

Dr. Carroll has extensive experience in ultraviolet and photonic science. Prior to joining Aerobiotix, he led the research and development group at Sunstar Engineering. He has a Ph.D. in chemistry from Columbia University and did his postdoctoral fellowship under Nobel laureate Prof. Ben Feringa at the University of Groningen, Netherlands, and Lawrence Berkeley National Laboratory.

TONY EMBREE

Chief Commercial Officer

Tony leads our global sales organization and commercialization strategy. Prior joining Aerobiotix, he was Senior Manager of Strategy at Stryker. He has led sales and marketing teams in multiple organizations including SurgiCount Medical, part of Patient Safety Technologies, INC (PSTX) as it expanded from 8 hospitals in 2008 to user base of 330 hospitals at time of acquisition in 2013.

COURTNEY ADAMS, Ph.D.

VP of Clinical and Medical Affairs

Dr. Adams leads our global clinical research and education initiatives as well as developing key opinion leaders to support our clinical mission. Prior to joining Aerobiotix, she held leading research and medical affairs roles at Biogen, Axogen, and MedPace. Dr. Adams holds Ph.D. in Pharmacology from University of Cincinnati.

ANTHONY DEFALCO

Vice President of Engineering

Anthony is a topflight medical device product development engineer and leader, experienced in the development and implementation of orthopedic, environmental, and electromechanical systems.

NATHAN UTZ

Vice President of Sales

Nathan brings a high level of commitment to servicing and building client relations. He was one of the first employees to start for Aerobiotix. Nathan has previously held leadership roles in the medical device industry. He received his BS from Antioch McGregor University Midwest.

MICHAEL SCHMITZ

Chief Financial Officer

Mr. Schmitz is a highly experienced financial practitioner with financial leadership roles in diverse industries including manufacturing and technology as well as a background in public accounting. He received his BS in accounting, cum laude, from the Miami University of Ohio. Mr. Schmitz is a certified public accountant and certified management accountant.